CATAPULT GROUP INTERNATIONAL LIMITED (CAT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAT - CATAPULT GROUP INTERNATIONAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Technology Hardware & Equipment
Index: ALL-ORDS | ALL-TECH

Catapult Group develops and sells wearable sensors to monitor and analyse athletic performance, including fitness and skill levels, injury risks and rehabilitation assistance. It listed on the ASX in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.97

23 Sep
2021

0.050

OPEN

$1.92

2.60%

HIGH

$1.97

251,093

LOW

$1.92

TARGET
$2.45 24.4% upside
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
CAT: 1
Title FY22
Forecast		 FY23
Forecast
EPS (cps) - 1.1 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 20162017201820192021
EPS Basic xxxxxxxxxxxx-8.5
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx93.1 M
Book Value Per Share xxxxxxxxxxxx52.5
Net Operating Cash Flow xxxxxxxxxxxx19.6 M
Net Profit Margin xxxxxxxxxxxx-17.58 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20162017201820192021
Return on Assets xxxxxxxxxxxx-9.73 %
Return on Equity xxxxxxxxxxxx-14.77 %
Return on Total Capital xxxxxxxxxxxx-13.78 %
Capex xxxxxxxxxxxx10.6 M
Capex % of Sales xxxxxxxxxxxx11.33 %
Free Cash Flow ex dividends xxxxxxxxxxxx17.1 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

25/06/2021

1

Add

$2.45

24.37%

Morgans sees the acquisition of UK-based SBG as strategically sound. It’s considered likely to increase the moat around the Catapult Group International's business, significantly improving annual contract value (ACV) and topline growth.

The company has completed an around US$43m capital raise. This, combined with the current cash balance, enables a ramp-up of both product and sales/operational spend in the next two years, explains the broker.

However, the analyst cautions a timeframe and path to achieve an acceptable return on investment (ROI) needs to be better annunciated. The Add rating is maintained and the target price falls to $2.45 from $2.46.

FORECAST
Morgans forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -1.07 cents.
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -0.94 cents.
Access Stockbroker Research History >

CAT STOCK CHART

FNArena News on CAT

1
Rudi’s View: Telstra, Iress, NextDC And That Grand Delusion

Sep 23 2021 - Rudi's View
2
Australian Broker Call *Extra* Edition – Jul 27, 2021

Jul 27 2021 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Jul 23, 2021

Jul 23 2021 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Jun 28, 2021

Jun 28 2021 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Mar 17, 2021

Mar 17 2021 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
2
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
3
Breakout For Cochlear

Aug 10 2021 - Technicals
4
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia
5
Treasure Chest: Has Nanosonics Been Too Successful?

Jul 08 2021 - Treasure Chest
6
Opportunity For ResMed Following Philips Recall

Jun 16 2021 - Australia
7
Treasure Chest: How Much Covid Impact For Nanosonics?

May 13 2021 - Treasure Chest
8
Who Will Be The Next Pro Medicus?

May 13 2021 - Weekly Reports
9
New Product, Patient Growth Key To ResMed

May 03 2021 - Australia
10
Growth For ResMed Despite Challenges

Feb 01 2021 - Australia